Literature DB >> 20981804

BK virus sequences in specimens from aborted fetuses.

Renzo Boldorini1, Sara Allegrini, Umberto Miglio, Ilenia Nestasio, Alessia Paganotti, Claudia Veggiani, Guido Monga, Valeria Pietropaolo.   

Abstract

Given the conflicting results of the few published studies, the aim of this retrospective molecular-based study of 10 aborted fetuses that underwent complete autopsy and 10 placentas was carried out to determine whether BK polyomavirus (BKV) can be transmitted transplacentally. The interruption of pregnancy was due to a miscarriage (five cases) or a prenatal diagnosis of severe intrauterine malformations (five cases). Samples from the brain, heart, lung, thymus, liver, and kidney were taken from each fetus, and two samples were obtained from all of the placentas. The presence of BKV was investigated by means of PCR using primers specific for the transcription control region (TCR) and viral capsidic protein 1 (VP1) and DNA extracted from formalin-fixed, paraffin-embedded tissue. BKV genome was detected in 22 of 60 samples (36.6%) from seven fetuses (70%), regardless of the cause of abortion: VP1 was amplified in 12 samples (54%), TCR in seven (32%), and both in three (14%). VP1 was also detected in one placental sample. BKV sequences were most frequently detected in heart and lung (five cases), but sequence analyses of TCR and VP1 revealed a high degree of genomic variability among the samples taken from different organs and the placenta. These results indicate that BKV can cross the placenta during pregnancy and become latent in fetal organs other than the kidney and brain (previously considered the main targets of BKV latency). This may happen in early pregnancy and does not seem to be associated with an increased risk of abortion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20981804     DOI: 10.1002/jmv.21923

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  The human fetal glial cell line SVG p12 contains infectious BK polyomavirus.

Authors:  Stian Henriksen; Garth D Tylden; Alexis Dumoulin; Biswa Nath Sharma; Hans H Hirsch; Christine Hanssen Rinaldo
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

Review 2.  BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.

Authors:  George R Ambalathingal; Ross S Francis; Mark J Smyth; Corey Smith; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

3.  Exposure to raccoon polyomavirus (RacPyV) in free-ranging North American raccoons (Procyon lotor).

Authors:  M E Church; F N Dela Cruz; M Estrada; C M Leutenegger; P A Pesavento; K D Woolard
Journal:  Virology       Date:  2016-01-21       Impact factor: 3.616

4.  Neutralizing and IgG antibodies against simian virus 40 in healthy pregnant women in Italy.

Authors:  Manola Comar; Connie Wong; Mauro Tognon; Janet S Butel
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

5.  Serum IgG Antibodies from Pregnant Women Reacting to Mimotopes of Simian Virus 40 Large T Antigen, the Viral Oncoprotein.

Authors:  Elisa Mazzoni; Mariantonietta Di Stefano; Josè R Fiore; Federica Destro; Marco Manfrini; John Charles Rotondo; Maria V Casali; Fortunato Vesce; Pantaleo Greco; Gennaro Scutiero; Fernanda Martini; Mauro G Tognon
Journal:  Front Immunol       Date:  2017-04-10       Impact factor: 7.561

Review 6.  Human polyomavirus reactivation: disease pathogenesis and treatment approaches.

Authors:  Cillian F De Gascun; Michael J Carr
Journal:  Clin Dev Immunol       Date:  2013-05-02

Review 7.  The role of infection in miscarriage.

Authors:  Sevi Giakoumelou; Nick Wheelhouse; Kate Cuschieri; Gary Entrican; Sarah E M Howie; Andrew W Horne
Journal:  Hum Reprod Update       Date:  2015-09-19       Impact factor: 15.610

Review 8.  Role of BK human polyomavirus in cancer.

Authors:  Jorge Levican; Mónica Acevedo; Oscar León; Aldo Gaggero; Francisco Aguayo
Journal:  Infect Agent Cancer       Date:  2018-04-05       Impact factor: 2.965

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.